• To identify the maximum tolerated dose (MTD) of AZD8931 following repeated twice daily administration, by assessment of dose limiting toxicities (DLT) [ Designated as safety issue: No ]
• To explore the pharmacokinetics (PK) of single doses of AZD8931 in patients with advanced solid malignancies [ Designated as safety issue: No ]
• To explore the pharmacokinetics (PK) of multiple doses of AZD8931 in patients with advanced solid malignancies [ Designated as safety issue: No ]

• To identify the MTD of AZD8931 following repeated twice daily administration, by assessment of DLT. [ Designated as safety issue: No ]
• To explore the PK of single doses of AZD8931 in patients with advanced solid malignancies. [ Designated as safety issue: No ]
• To explore the PK of multiple doses of AZD8931 in patients with advanced solid malignancies. [ Designated as safety issue: No ]

The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies

Inclusion Criteria:

• Cancer which is refractory to standard therapies, or for which no standard therapies exist. Inclusion is irrespective of stage of disease or extent of prior therapy.
• Histologically or cytologically confirmed solid, malignant tumour.

Exclusion Criteria:

• Receipt of any of the following treatments within 4 weeks prior to study entry: chemotherapy (within 6 weeks for nitrosurea or mitomycin C), radiotherapy, hormone therapy (except for androgen-deprivation therapy for patients with prostate cancer), immunotherapy and any other anti-cancer therapies.
• Unresolved toxicity (other than stable toxicity) from previous anti-cancer therapy, except alopecia.
• History of documented cardiac failure, angina pectoris requiring antianginal medication, evidence of transmural infarction on ECG, poorly controlled hypertension (systolic >180 mmHg or diastolic >100 mmHg), significant valvular disease or history of high risk dysrrhythmia (such as ventricular fibrillation or ventricular tachycardia [includes ventricular triplets]).
• Resting ECG with measurable QTc interval of > 460 msec at 2 or more time-points within a 24-hour time period, or history of prolonged QTc syndrome.
• The presence of any ocular disease or condition that is active or is likely to flare up during the course of the study or any systemic disease/condition that is affecting or has affected the eye in the past and may flare up, or the treatment of which may have an adverse effect on the eye. Eye conditions that are stable and of long standing, such as scars from trauma, pinguecula, atrophic pterygia etc, should not be considered as reasons to exclude the patient.